Answers are grounded in this paper and cite their sources.
Cutaneous melanoma is an aggressive skin cancer for which localized treatment remains difficult because of limited drug penetration through the stratum corneum and the systemic toxicity of conventional chemotherapy. Here, we developed a noninvasive physicochemical platform combining hyaluronic acid (HA)-functionalized paclitaxel-loaded solid lipid nanoparticles (SLNs) with high-intensity focused ultrasound (HIFU) for localized melanoma therapy. The optimized SLNs exhibited a hydrodynamic diameter of 134.6 ± 4.2 nm and a zeta potential of –22.3 ± 1.5 mV. HIFU induced changes in the structural organization of the lipid matrix, accelerating paclitaxel release and enhancing skin penetration. In vitro, SLNs with HIFU reduced B16F10 melanoma cell viability to below 20% while maintaining approximately 65% viability of HaCaT keratinocytes. The combined treatment increased intracellular ROS generation by 6.2-fold and enhanced apoptotic signaling. In ex vivo porcine skin, HIFU-assisted delivery of coumarin-6-loaded SLNs increased fluorescence penetration to approximately 1500 μm, compared with 750 μm without HIFU. In B16F10 tumor-bearing mice, topical SLNs combined with HIFU under mild hyperthermia (41–43 °C) achieved 90.1% tumor growth inhibition at Day 8, 81.5% tumor necrosis, and 86.5% TUNEL-positive cells without significant body-weight loss or treatment-related toxicity. These findings support HIFU-enhanced SLNs as a potential strategy for improving cutaneous paclitaxel delivery and suppressing localized melanoma growth.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: